Technical Analysis for HTBX - Heat Biologics, Inc.

Grade Last Price % Change Price Change
D 7.98 0.88% 0.07
HTBX closed up 0.88 percent on Friday, February 26, 2021, on 23 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down
Historical HTBX trend table...

Date Alert Name Type % Chg
Lizard Bullish Bullish Day Trade Setup 0.00%
Doji - Bullish? Reversal 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 200 DMA Bearish 0.88%
Wide Bands Range Expansion 0.88%
Oversold Stochastic Weakness 0.88%
Crossed Above 200 DMA Bullish -5.67%
Stochastic Reached Oversold Weakness -5.67%
Wide Bands Range Expansion -5.67%
Older End-of-Day Signals for HTBX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% 3 days ago
Down 2 % 3 days ago
Down 1% 3 days ago
Fell Below Previous Day's Low 3 days ago
Up 2% 3 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Heat Biologics, Inc. Description

Heat Biologics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. It is developing Immune Pan Antigen Cytotoxic therapy, a platform technology that delivers human cells that are reprogrammed to pump out various cancer associated antigens together with a potent immune adjuvant. The company's products under development include HS-110 that is in Phase II clinical trials for the treatment of non-small cell lung cancer; HS-410 for the bladder cancer treatment; HS-310 to treat ovarian cancer; and HS-510 for treating triple negative breast cancer. Its products also comprise HS-HIV product candidate for the treatment and prevention of HIV. The company was founded in 2008 and is based in Chapel Hill, North Carolina.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Infectious Diseases Treatment Of Cancer Cancers Breast Cancer Treatment Of Breast Cancer Small Cell Lung Cancer Ovarian Cancer Non Small Cell Lung Cancer Vaccine Cancer Treatment Vaccination HIV Platform Technology Bladder Cancer Cancer Vaccine Treatment Of Non Small Cell Lung Cancer Triple Negative Breast Cancer Chapel Hill Heat Biologics Neuvenge

Is HTBX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 30.1
52 Week Low 3.045
Average Volume 3,048,606
200-Day Moving Average 8.40
50-Day Moving Average 7.35
20-Day Moving Average 9.03
10-Day Moving Average 9.29
Average True Range 1.07
ADX 32.27
+DI 33.52
-DI 27.88
Chandelier Exit (Long, 3 ATRs ) 13.79
Chandelier Exit (Short, 3 ATRs ) 9.78
Upper Bollinger Band 12.37
Lower Bollinger Band 5.68
Percent B (%b) 0.34
BandWidth 74.07
MACD Line 0.29
MACD Signal Line 0.63
MACD Histogram -0.3447
Fundamentals Value
Market Cap 1.28 Billion
Num Shares 160 Million
EPS -0.65
Price-to-Earnings (P/E) Ratio -12.20
Price-to-Sales 21.18
Price-to-Book 1.50
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.81
Resistance 3 (R3) 8.76 8.43 8.67
Resistance 2 (R2) 8.43 8.22 8.46 8.62
Resistance 1 (R1) 8.21 8.09 8.26 8.26 8.58
Pivot Point 7.88 7.88 7.91 7.91 7.88
Support 1 (S1) 7.66 7.67 7.71 7.71 7.38
Support 2 (S2) 7.33 7.54 7.36 7.34
Support 3 (S3) 7.11 7.33 7.29
Support 4 (S4) 7.16